A lot of people follow/know more than I, especially Biotech Jim! I don't have a position in the company though I've been interested in it for some time (at preferably much lower stock price).
With those caveats... I was surprised Omidria revenue growth held up! I was expecting a weak quarter. I realize everyone values 721 more (I don't disagree) however I thought a weak quarter would spook people even more then the reimbursement change coming in 2018.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.